From: Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Drug | Brand name | Manufacturer | Targets | Applications of diseases | Approved years or current phase of clinical trials |
---|---|---|---|---|---|
Erdafitinib | Balversa | Janssen | FGFR1-4 | FGFR2/3-alterated locally advanced or metastatic urothlial cancer that has progressed during or following platinum-containing chemotherapy | 2019 [166] |
Pemigatinib | Pemazyre | Incyte | FGFR1-3 | Previously treated, unresectable locally advanced or metastatic CCA with FGFR2 fusion+ or other rearrangement | 2020 [167] |
Investigational drugs | |||||
Futibatinib | - | Taiho Oncology | FGFR1-4 | FGFR2-rearranged advanced intrahepatic CCA | III (NCT04093362) |
FGFR1-4 rearranged solid tumors | II (NCT04189445) | ||||
FGFR-amplifiled MBC | II (NCT04024436) | ||||
Infigratinib | - | Novartis Oncology | FGFR1-3 | previously treated advanced FGFR3-rearranged urothlial cancer previously treated advanced FGFR2-rearranged CCA | II [164] II [168] |